Literature DB >> 30292756

Probing structure-activity relationship in β-arrestin2 recruitment of diversely substituted adenosine derivatives.

Jolien Storme1, Dilip K Tosh2, Zhan-Guo Gao2, Kenneth A Jacobson2, Christophe P Stove3.   

Abstract

In the adenosine receptor (AR) subfamily of G protein-coupled receptors (GPCRs), biased agonism has been described for the human A1AR, A2BAR and A3AR. While diverse A3AR agonists have been evaluated for receptor binding and Gi-mediated cAMP signalling, the β-arrestin2 (βarr2) pathway has been left largely unexplored. We screened nineteen diverse adenosine derivatives for βarr2 recruitment using a stable hA3AR-NanoBit®-βarr2 HEK293T cell line. Their activity profiles were compared with a cAMP accumulation assay in stable hA3AR CHO cells. Structural features linked to βarr2 activation were further investigated by the evaluation of an additional ten A3AR ligands. The A3AR-selective reference agonist 2-Cl-IB-MECA, which is a full agonist in terms of cAMP inhibition, only showed partial agonist behaviour in βarr2 recruitment. Highly A3AR-selective (N)-methanocarba 5'-uronamide adenosine derivatives displayed higher potency in both cAMP signalling and βarr2 recruitment than reference agonists NECA and 2-Cl-IB-MECA. Their A3AR-preferred conformation tolerates C2-position substitutions, for increased βarr2 efficacy, better than the flexible scaffolds of ribose derivatives. The different amino functionalities in the adenosine scaffold of these derivatives each seem to be important for signalling as well. In conclusion, we have provided insights into ligand features that can help to guide the future therapeutic development of biased A3AR ligands with respect to G-protein and βarr2 signalling.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  A(3) adenosine receptor; Biased signaling; G protein-coupled receptor; Structure-activity relationship; β-arrestin2

Mesh:

Substances:

Year:  2018        PMID: 30292756      PMCID: PMC6530469          DOI: 10.1016/j.bcp.2018.10.003

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  66 in total

Review 1.  Biochemical methods for detection and measurement of cyclic AMP and adenylyl cyclase activity.

Authors:  S R Post; R S Ostrom; P A Insel
Journal:  Methods Mol Biol       Date:  2000

2.  A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.

Authors:  M L Trincavelli; D Tuscano; M Marroni; A Falleni; V Gremigni; S Ceruti; M P Abbracchio; K A Jacobson; F Cattabeni; C Martini
Journal:  Mol Pharmacol       Date:  2002-12       Impact factor: 4.436

3.  (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.

Authors:  Susanna Tchilibon; Bhalchandra V Joshi; Soo-Kyung Kim; Heng T Duong; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

4.  Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence.

Authors:  L M Bohn; R R Gainetdinov; F T Lin; R J Lefkowitz; M G Caron
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

5.  An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

Authors:  C E Groer; K Tidgewell; R A Moyer; W W Harding; R B Rothman; T E Prisinzano; L M Bohn
Journal:  Mol Pharmacol       Date:  2006-11-07       Impact factor: 4.436

Review 6.  Medicinal chemistry of adenosine A3 receptor ligands.

Authors:  Christa E Müller
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

7.  Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.

Authors:  Huijun Wei; Seungkirl Ahn; Sudha K Shenoy; Sadashiva S Karnik; László Hunyady; Louis M Luttrell; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-29       Impact factor: 11.205

8.  Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.

Authors:  K A Jacobson; X Ji; A H Li; N Melman; M A Siddiqui; K J Shin; V E Marquez; R G Ravi
Journal:  J Med Chem       Date:  2000-06-01       Impact factor: 7.446

9.  N6-Substituted adenosine derivatives: selectivity, efficacy, and species differences at A3 adenosine receptors.

Authors:  Zhan-Guo Gao; Joshua B Blaustein; Ariel S Gross; Neli Melman; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2003-05-15       Impact factor: 5.858

10.  Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.

Authors:  Zhan-Guo Gao; Soo-Kyung Kim; Thibaud Biadatti; Wangzhong Chen; Kyeong Lee; Dov Barak; Seong Gon Kim; Carl R Johnson; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-09-26       Impact factor: 8.039

View more
  8 in total

1.  Luciferase Complementation Approaches to Measure GPCR Signaling Kinetics and Bias.

Authors:  Nicola C Dijon; Desislava N Nesheva; Nicholas D Holliday
Journal:  Methods Mol Biol       Date:  2021

2.  A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity.

Authors:  Dilip K Tosh; Veronica Salmaso; Ryan G Campbell; Harsha Rao; Amelia Bitant; Eline Pottie; Christophe P Stove; Naili Liu; Oksana Gavrilova; Zhan-Guo Gao; John A Auchampach; Kenneth A Jacobson
Journal:  Eur J Med Chem       Date:  2021-11-19       Impact factor: 6.514

3.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

4.  Assessment of biased agonism at the A3 adenosine receptor using β-arrestin and miniGαi recruitment assays.

Authors:  Eline Pottie; Dilip K Tosh; Zhan-Guo Gao; Kenneth A Jacobson; Christophe P Stove
Journal:  Biochem Pharmacol       Date:  2020-03-26       Impact factor: 5.858

Review 5.  Purinergic Signaling: Impact of GPCR Structures on Rational Drug Design.

Authors:  Veronica Salmaso; Kenneth A Jacobson
Journal:  ChemMedChem       Date:  2020-09-18       Impact factor: 3.540

6.  2‑Cl‑IB‑MECA regulates the proliferative and drug resistance pathways, and facilitates chemosensitivity in pancreatic and liver cancer cell lines.

Authors:  Jana Kotulova; Katerina Lonova; Agata Kubickova; Jana Vrbkova; Pavla Kourilova; Marian Hajduch; Petr Dzubak
Journal:  Int J Mol Med       Date:  2022-01-18       Impact factor: 4.101

Review 7.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

8.  Treatment of chronic neuropathic pain: purine receptor modulation.

Authors:  Kenneth A Jacobson; Luigino Antonio Giancotti; Filomena Lauro; Fatma Mufti; Daniela Salvemini
Journal:  Pain       Date:  2020-07       Impact factor: 7.926

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.